# US 2024/0082207 A1 · Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0082207 A1
- Document ID: US20240082207A1
- Status: Published application
- Kind: A1
- Application number: 18/210,992
- Filed: 2023-06-16
- Published: 2024-03-14
- Earliest claimed: 2016-08-31
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: David R. Elmaleh; Rudolph E. Tanzi; Timothy M. Shoup; Ana Gircluc
- Web page: https://patentgrep.com/patent/US20240082207A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 311/22: with oxygen or sulfur atoms directly attached in position 4
- C07D 311/24: with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

## Claims

### Claim 1

A method of treating a neuron inflammation condition in a patient in need thereof comprising administering to the patient a therapeutically effective amount of at least one compound selected from:
wherein the neuron inflammation condition is amyotrophic lateral sclerosis (ALS), Huntington's Disease, Parkinson's disease (PD), ischemic stroke, or a condition associated with prion disease.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the neuron inflammation condition is ALS.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the neuron inflammation is Huntington's Disease.

### Claim 6 (depends on 1)

The method in claim 1, wherein the neuron inflammation is Parkinson's disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the neuron inflammation condition is ischemic stroke.

### Claim 8 (depends on 1)

The method of claim 1, wherein the neuron inflammation condition is associated with prion disease.

### Claim 9 (depends on 3)

The method of claim 3, wherein the compound is administered via IP and/or IV.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound is administered transdermally.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound is administered by inhalation.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound is administered at a dose between about 1 mg and about 1000 mg per day.

### Claim 13 (depends on 1)

The method of claim 1, where in the compound is administered at a dose of about 10, about 20, about 30, about 50, about 100, or about 500 mg per day.

### Claim 14 (depends on 3)

The method of claim 3, further comprising co-administering a second compound selected from CD4+; siRNA; miRNA that ameliorates ALS; glial morphology modifier; SOD1 control; and Riluzole.

### Claim 15 (depends on 3)

The method of claim 3, further comprising co-administering a second compound selected from an anti-aggregation drug and a targeting drug for AD.

### Claim at position 16

16-18. (canceled)

### Claim 19 (depends on 3)

The method of claim 3, further comprising co-administering a second compound selected from an antibody targeting drug that ameliorates ALS.

### Claim 20 (depends on 3)

The method of claim 3, further comprising co-administering a second compound selected from an anti-inflammatory targeting drug that ameliorates ALS.

### Claim 21 (depends on 1)

The method of claim 1, further comprising co-administering a second compound selected from a targeting drug that ameliorates neurodegeneration associated with amyloidosis or tauopathies.

### Claim 22 (depends on 6)

The method of claim 6, further comprising co-administering a second compound selected from an alpha synuclein targeting drug that ameliorates PD and a Parkinson's targeting drug that ameliorates PD.
